The Latest “Buzz on the Street” Show: Featuring Blueberries Medical (CSE: BBM) Acquisition

FinancialBuzz.com’s latest Buzz on the Street Show: Featuring Our Corporate News Recap on “Blueberries Medical to Acquire Cannabis Cultivation, Processing & Manufacturing Rights for 3.2 Million Square Foot Property in Argentina”

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) a leading Colombia based licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce that the Company has entered into a binding agreement effective March 25, 2019, to acquire cannabis cultivation, processing, manufacturing, export and other rights in Argentina from BBV Labs Inc.

Blueberries Medical is seeking to become a large-scale producer of naturally grown premium-quality cannabis with its primary operations well situated in the Bogota savanna in central Colombia. Lead by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology, and marketing, Blueberries has received all licenses required for the cultivation, production, domestic distribution and international export of cannabidiol (CBD) and tetrahydrocannabinol-based (THC) medical cannabis.

The expansion of the cannabis industry has led companies involved in the marketplace to expand internationally as larger players are extending their operations into other regions such as Europeand Latin America. Cannabis is enjoying a global perspective shift on legalization, however, the industry is still heavily hindered by certain regulations. Nonetheless, many countries are exploring opportunities within the market for medical applications. Despite its continued global expansion, the U.S. continues to dominate the cannabis marketplace. According to Verified Market Intelligence, the global marijuana market was valued at USD 42.20 Billion in 2017 and is expected to reach USD 466.81 Billion by 2025. Additionally, the market is projected to register a CAGR of 35.3% throughout the forecast period from 2018 to 2025. The market is primarily being accelerated by the growing adoption of medical cannabis for the treatment of chronic diseases. However, as more U.S. states begin to legalize recreational cannabis, projections show that recreational sales could overtake medical sales in the near future. 

Europe and the LATAM region are attractive regions for many companies to establish operations. Europe’s overall cannabis market is projected to reach USD 66.8 Billion within the next five years, while the LATAM region is expected to reach USD 12.7 Billion in sales by 2028, according to Prohibition Partners. The research notes that several European countries have passed medical marijuana legislation recently, and there is a 50% chance a few more could pass recreational laws. Meanwhile, the LATAM region is being targeted mainly for cultivation facilities due to its fertile lands and inexpensive costs associated with growing, as more countries view legalization with zest. “As more markets open, international trade begins and research and science take a front seat in the coming years,” said John Billings, head of cultivation for The Farm Dispensary. “There’s no reason to think this trend will not continue. Growing plants/varietals with higher concentrate returns will help keep production costs down. You have old players (IsraelJamaica, GW Pharmaceuticals and the U.S.) and new players (Canada and Mexico) coming into the scene with their own ideas and plans.”

For more information, please visit: Blueberries Medical Corp.

For more corporate news on Blueberries Medical Corp., check out the Buzz on the Street

About Buzz on the Street: One of FinancialBuzz.com’s latest corporate and financial news shows, covering the latest trending stock market news. Buzz on the Street looks to become a leader in corporate video news dissemination. Buzz on the Street is 100% original content, brought to you by Financial Buzz Media.

Sponsored Content Release. Click for Full Disclosure

3 Comments
  1. Allison Gottlieb 4 months ago
    Reply

    Cannabis was used as a medical treatment in the U.S. in the 1700’s. Physicians used it to treat skin inflammation and other health issues. Today patients with a qualifying condition can use medical cannabis to treat their daily symptoms.

    • Marcy Nicholson 4 months ago
      Reply

      #MedicalCannabis #HealthScience and practice: dosing precision is of basic importance; potential benefits are missed due to lack of knowledge of specific mechanisms and combinations. #CannabinoidScience

    • Tim Milgram 4 months ago
      Reply

      Tom Brokaw, the 79-year-old former anchor is in remission from multiple myeloma and uses medical marijuana for cancer pain relief

Leave a Comment

  • Sponsored Content Release

    FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: FinancialBuzz.com is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on http://www.FinancialBuzz.com (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content), FinancialBuzz.com, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. FinancialBuzz.com receives fees for producing and presenting high quality and sophisticated content on FinancialBuzz.com along with other financial news PR media services. FinancialBuzz.com does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. FinancialBuzz.com only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For blueberries medical corp. financial and corporate news dissemination, FinancialBuzz.com has been compensated ten thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. FinancialBuzz.com will always disclose any compensation in securities or cash payments for financial news PR advertising. FinancialBuzz.com does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security. FinancialBuzz.com, members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. FinancialBuzz.com. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by FinancialBuzz.com constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by FinancialBuzz.com. Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: http://www.financialbuzz.com.